Search Within

Sham Mailankody

Formats
  1. Meeting Abstract (169)
  2. Journal Article (95)
  3. Research Letter (12)
  4. Review (10)
  5. Correspondence (4)
  6. Editorial (2)
  7. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (293)
  2. Department of Medicine (293)
  3. Hematologic Malignancies, Division of (293)
  4. Myeloma (293)
  5. Survivorship Research (212)
  6. Hematologic Malignancies Research (209)

More Groups

People
  1. Neha Korde (188)
  2. Alexander Lesokhin (167)
  3. Hani Hassoun (160)
  4. Sergio Giralt (158)
  5. Malin Hultcrantz (155)
  6. Heather Landau (144)

More People

Years
  1. 2025 (9)
  2. 2024 (46)
  3. 2023 (49)
  4. 2022 (44)
  5. 2021 (22)
  6. 2020 (22)

More Years

Publications
  1. Blood (95)
  2. Clinical Lymphoma, Myeloma and Leukemia (46)
  3. Journal of Clinical Oncology (23)
  4. JAMA Oncology (12)
  5. Blood Cancer Journal (11)
  6. Leukemia and Lymphoma (10)

More Publications

Publishers
  1. American Society of Hematology (105)
  2. Elsevier Inc. (70)
  3. Nature Publishing Group (25)
  4. American Society of Clinical Oncology (24)
  5. American Medical Association (18)
  6. Taylor & Francis Group (10)

More Publishers

Results (293)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Results from the first phase 1 clinical study of the B-cell maturation antigen (BCMA) NEX T chimeric antigen receptor (CAR) T cell therapy CC-98633/BMS-986354 in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Costa, L. J.; Kumar, S. K.; Atrash, S.; Liedtke, M.; Kaur, G.; Derman, B. A.; Bergsagel, P. L.; Mailankody, S.; McCarthy, P. L.; Limones, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Genomic determinants of resistance in newly diagnosed multiple myeloma treated with targeted-immunotherapy
    Meeting Abstract

    Maura, F.; Boyle, E.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Blaney, P.; Gagler, D.; Ziccheddu, B.; Ghamlouch, H.; Wang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Fc-mediated antibody effector function, inflammation resolution and oligoclonality on TCR rearrangements predict sustained MRD negativity in newly diagnosed multiple myeloma treated with immunotherapy regimens
    Meeting Abstract

    Boyle, E. M.; Maura, F.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Ghamlouch, H.; Gagler, D.; Blaney, P.; Ziccheddu, B.; Wang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Stem cell autograft minimal residual disease negativity improves outcomes after autotransplant for multiple myeloma
    Meeting Abstract

    Nishimura, N.; Brown, S.; Devlin, S. M.; Dahi, P. B.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Hassoun, H.; Hultcrantz, M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy
    Correspondence

    Nath, K.; Shekarkhand, T.; Salcedo, M.; Derkach, A.; Rueda, S.; Chansakul, A.; Hulcrantz, M.; Korde, N.; Shah, U. A.; Tan, C.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Sustained minimal residual disease negativity in multiple myeloma is associated with stool butyrate and healthier plant-based diets
    Journal Article

    Shah, U. A.; Maclachlan, K. H.; Derkach, A.; Salcedo, M.; Barnett, K.; Caple, J.; Blaslov, J.; Tran, L.; Ciardiello, A.; Burge, M.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • GPRC5D-targeted CAR T cells for myeloma: The author's reply
    Correspondence

    Mailankody, S.; Brentjens, R. J.; Smith, E. L.
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Clinical trial participation among older adult Medicare fee-for-service beneficiaries with cancer
    Journal Article

    Green, A. K.; Tabatabai, S. M.; Aghajanian, C.; Landgren, O.; Riely, G. J.; Sabbatini, P.; Bach, P. B.; Begg, C. B.; Lipitz-Snyderman, A.; Mailankody, S.
    JAMA Oncology (2022)

    Fulltext@MSK | Save
  • Ethical challenges with CAR T slot allocation with idecabtagene vicleucel manufacturing access
    Meeting Abstract

    Kourelis, T.; Bansal, R.; Patel, K. K.; Berdeja, J. G.; Raje, N. S.; Alsina, M.; Cohen, A. D.; Siegel, D. S. D.; Mailankody, S.; Htut, M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinical efficacy of daratumumab (DARA)-based second line therapy after DARAcontaining and DARA-free induction therapies in multiple myeloma: A single center experience
    Meeting Abstract

    Ciardiello, A.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Lu, S. X.; Patel, D.; Maclachlan, K.; Lahoud, O. B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save